Investors

AIM Rule 26 Information

This area of the web site contains all information which is required to be disclosed in accordance with Rule 26 of the AIM Rules.

Shareholder Information

Other Exchanges and Trading Platforms
Shares in Issue
Significant Shareholdings
Director Shareholdings
Shares Not in Public Hands
Restrictions in Transfer of AIM Securities
UK City Code on Takeovers and Mergers

see Shareholder Information

Advisors

see Advisors

Announcements and Notifications

see News

Q&A with LungLife AI's CEO, Paul Pagano

Half-year Report For The Six Months Ended 30 June 2023

Featured News

February 4, 2025

Operational and Funding Update and Proposed Cancellation from AIM

LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides the following update. As set out in the Operational Update on 19 November 2024, the Company had been actively engaged in discussions with several potential strategic partners. These discussions were aimed at identifying a partner that not only shares the Company’s […]

• Read More

November 19, 2024

Operational update

Strong progress towards commercialisation of LungLB® LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer, provides an update on its operational progress made since the release of its interim results announcement. The Company has continued to execute on the commercial proof of concept of LungLB® and to explore opportunities for a suitable […]

• Read More

1 2 3 … 37 Next »

More News